CG
TNDM icon

Caprock Group’s Tandem Diabetes Care TNDM Stock Holding History

Caprock Group’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,831
Closed -$326K – 1293
2025
Q4 		$326K Sell
14,831
-29,528
-67% -$533K 0.01% 967
2025
Q3 		$555K Buy
+44,359
New +$600K 0.01% 770
2020
Q3 		– Sell
-2,505
Closed -$248K – 452
2020
Q2 		$248K Buy
+2,505
New +$200K 0.04% 322

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caprock Group's TNDM Position: Q1 2026 in Review

Caprock Group sold out of Tandem Diabetes Care (TNDM) in Q1 2026, closing a stake of 14,831 shares — an estimated $326K sold.

Caprock Group first reported a position in TNDM in Q2 2020 and held it in 3 quarters. The position peaked at $555K in Q3 2025. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

  • Caprock Group reported no remaining Tandem Diabetes Care position as of Q1 2026 after selling out during the quarter.
  • Caprock Group sold 14,831 Tandem Diabetes Care shares in Q1 2026, an estimated $326K.
  • Caprock Group first reported a position in Tandem Diabetes Care in Q2 2020 and held it in 3 quarters.
  • Caprock Group's Tandem Diabetes Care position peaked at $555K in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.